CN105273209B - 一种改性壳聚糖与聚(2-丙烯酰胺-2-甲基丙磺酸)复合微球的制备 - Google Patents
一种改性壳聚糖与聚(2-丙烯酰胺-2-甲基丙磺酸)复合微球的制备 Download PDFInfo
- Publication number
- CN105273209B CN105273209B CN201410250398.4A CN201410250398A CN105273209B CN 105273209 B CN105273209 B CN 105273209B CN 201410250398 A CN201410250398 A CN 201410250398A CN 105273209 B CN105273209 B CN 105273209B
- Authority
- CN
- China
- Prior art keywords
- methyl propane
- acrylamide
- pamps
- chitosan
- microballoon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 62
- 239000004005 microsphere Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000004048 modification Effects 0.000 title claims abstract description 11
- 238000012986 modification Methods 0.000 title claims abstract description 11
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims abstract description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940014800 succinic anhydride Drugs 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 10
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 claims description 6
- 238000013019 agitation Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 2
- 239000005662 Paraffin oil Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 230000001804 emulsifying effect Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 239000003505 polymerization initiator Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 25
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 18
- 239000003431 cross linking reagent Substances 0.000 abstract description 12
- 229940009456 adriamycin Drugs 0.000 abstract description 8
- 239000011806 microball Substances 0.000 abstract description 7
- 125000003277 amino group Chemical group 0.000 abstract description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 4
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 3
- 239000000725 suspension Substances 0.000 abstract description 2
- FKOZPUORKCHONH-UHFFFAOYSA-N 2-methylpropane-1-sulfonic acid Chemical compound CC(C)CS(O)(=O)=O FKOZPUORKCHONH-UHFFFAOYSA-N 0.000 abstract 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000000542 sulfonic acid group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 235000019394 potassium persulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种改性壳聚糖(CS)与聚(2‑丙烯酰胺‑2‑甲基丙磺酸)(PAMPS)互穿网络复合微球的制备方法。首先制备壳聚糖与聚(2‑丙烯酰胺‑2‑甲基丙磺酸)混合物溶液，再以戊二醛作交联剂，通过反向悬浮的方法制备粒径集中分布在300‑500μm的互穿网络型CS/PAMPS复合微球，用丁二酸酐与复合微球反应，使CS中的游离氨基转变成羧基，以提高微球负载荷正电药物的能力。结果显示：改性CS/PAMPS复合微球可以快速并大量负载阿霉素，较其它微球有明显改善的载药潜力。
Description
技术领域
本发明涉及一种生物可降解的壳聚糖(CS)与聚(2-丙烯酰胺-2-甲基丙磺酸)(PAMPS)的复合微球制备，属于生物材料与缓释技术领域。
背景技术
肿瘤的介入疗法是将栓塞微球利用手术方式将其置入特定部位，通过阻断肿瘤供血和营养物质的供应，达到治疗癌症的目的。这种治疗方式的优点：对周身毒副作用较小；对肿瘤治疗彻底；避免癌细胞的再转移等。可是也有其固有缺陷，如：治疗周期长；会有疼痛、发热、呕吐等不良反应。为了增强对肿瘤细胞的杀伤力度，缩短治疗周期，很多学者开始尝试在栓塞微球上负载化疗药物，制备成载药栓塞微球。目前，栓塞微球负载药物的方式比较单一，最常用的载药方式是将化疗药物直接包覆在微球内部，通过扩散方式释放药物。这种载药方式的优点是载药量大且可以控制。由于化疗药物参与微球合成的多步反应，流失严重且部分药物分解失活，这也限制了该微球的推广。
为了改善现有载药微球的制备工艺，本实验选择新的载药方式：利用溶胀吸收和正负离子间的静电吸附作用，使药物快速负载。壳聚糖是一种生物相容性好，无毒，无害，可以生物降解的大分子，其与醛类反应所得微球溶胀性好，可生物降解，是比较理想的药物载体。2-丙烯酰胺-2-甲基丙磺酸(AMPS)是一种携带有磺酸基团和双键的有机物，其中双键可以在引发剂作用下打开发生聚合反应，形成聚(2-丙烯酰胺-2-甲基丙磺酸)。磺酸基在水中电离出氢离子显示负电性，可以和阿霉素分子发生静电吸附。本文利用反向悬浮交联法制备出PAMPS与壳聚糖的互穿网络型微球，为了减小载药过程中壳聚糖中游离氨基对阿霉素分子的屏蔽干扰，本发明中用丁二酸酐与壳聚糖中游离氨基反应，使其转变成羧基，最终得到改性互穿网络CS/PAMPS复合微球，以提高微球负载荷正电药物的能力。利用壳聚糖微球的良好溶胀性和磺酸基对阿霉素分子的静电吸附，达到快速大量载药的目的。
发明内容
本发明提供一种表面经功能化后可以通过静电吸附和溶胀吸收二重方式负载阿霉素的改性CS/PAMPS复合微球制备方法。首先制备了CS/PAMPS混合溶液，然后利用此混合液制备CS/PAMPS复合微球，并用丁二酸酐与微球中的游离氨基(-NH2)反应，制备出改性互穿网络CS/PAMPS复合微球，利用微球中的游离磺酸基团和羧基与氨基静电作用和微球良好的溶胀性来负载阿霉素。
本发明的有益效果：
①改性CS/PAMPS复合微球可以利用静电吸附和溶胀吸收两种方式负载药物，微球中富含羧基和磺酸基团，对于荷正电药物例如阿霉素载药量大、载药速度快、无泄漏。
②以壳聚糖为主要成分，微球可生物降解。
③通过改性CS/PAMPS复合微球，减小了壳聚糖中氨基对于阿霉素的屏蔽，提高了载药潜能。
附图说明
图1(a)交联剂戊二醛加入量为4.0g时的微球照片；(b)是交联剂加入量为6.0g时的CS微球照片；(c)是交联剂加入量为3.0g时的CS微球照片；(d)是交联剂加入量为6.0g时的CS微球照片。
图2不同微球的红外谱图；(a：CS微球；b：CS/PAMPS复合微球；c：丁二酸酐改性CS/PAMPS微球)。
图3不同微球在生理盐水中的直径变化曲线；(a：CS微球；b：CS/PAMPS复合微球；c：丁二酸酐改性CS/PAMPS微球)。
图4复合载药微球在不同pH的PBS缓冲溶液中的药物(阿霉素)释放曲线；(a：pH＝4.0；b：pH＝5.0；c：pH＝6.0；d：pH＝7.0；e：pH＝7.4)。
具体实施方式：
实施例1：CS/PAMPS混合溶液的制备：机械搅拌下，向48g蒸馏水中加入1g冰醋酸和2.0g壳聚糖(CS)，待完全溶解后加入2-丙烯酰胺-2-甲基丙磺酸(AMPS)，氮气保护下加入一定量的N，N-亚甲基双丙烯酰胺(MBA)和过硫酸钾(K2S2O8)，60℃下反应3小时，所得溶液呈乳白状。
实施例2：CS/PAMPS复合微球的制备：在烧杯中加入50mL石蜡油，机械搅拌下加入司班80和10mL上述混合液，30分钟后加入4.0g戊二醛溶液(25％)和1mL盐酸(36％)，25℃反应1.5小时，经抽滤、洗涤、干燥后得到CS/PAMPS复合微球。
实施例3：改性互穿网络CS/PAMPS复合微球的制备：取3.0g丁二酸酐溶于50mLDMF中，磁力搅拌下加入1.0g CS/PAMPS复合微球，于40℃下反应1.5h，经过滤、洗涤、干燥后得到改性复合微球。
实施例4：改性互穿网络CS/PAMPS复合载药微球的制备：配制浓度为0.25mg/mL的盐酸阿霉素溶液40mL，称取150mg改性CS/PAMPS复合微球放入其中，低速搅拌下进行药物负载反应。
实施例5：精确称取150mg改性CS/PAMPS复合微球5次，分别置于pH值为4.0、5.0、6.0、7.0和8.0的盐酸阿霉素溶液中，避光环境中磁力搅拌48小时。在不同时间点，用紫外分光计得出溶液中阿霉素的浓度。
实施例6：用光学显微镜对微球进行拍照，图1中a是交联剂加入量为4.0g时的CS微球照片；b是交联剂加入量为6.0g时的CS微球照片；c是交联剂加入量为3.0g时的CS微球照片；d是交联剂加入量为7.0g时的CS微球照片。结果显示：a、b和d中微球外观圆整，分散性良好。b与a相较，微球颜色明显加深，这是交联剂加入量增加导致的结果。由图可知交联剂的最佳加入量为4.0g。
实施例7：图2显示不同微球的红外谱图，a：CS微球；b：CS/PAMPS复合微球；c：丁二酸酐改性CS/PAMPS微球。
实施例8：图3中是不同微球在生理盐水中的直径变化曲线。a：CS微球；b：CS/PAMPS复合微球；c：丁二酸酐改性CS/PAMPS微球。结果显示：CS微球及其改性微球的溶胀性良好，溶胀平衡时微球直径可以增大到干燥状态时的2倍；用丁二酸酐修饰后的微球溶胀性较CS微球好；微球的溶胀性由其自身的特性及交联剂戊二醛的加入量所决定。丁二酸酐修饰后，亲水性基团(-COOH)的引入，导致微球的吸水性能提高，溶胀性变大。在CS/PAMPS复合微球中，亲水性基团(磺酸基团)的引入也会提高复合微球的溶胀性能。
实施例9：图4是改性互穿网络CS/PAMPS复合载药微球在不同pH下的缓冲溶液(PBS)中的药物释放曲线(a：pH＝4.0；b：pH＝5.0；c：pH＝6.0；d：pH＝7.0；e：pH＝7.4)。结果显示：在不同pH的PBS溶液中，改性CS/PAMPS复合载药微球对阿霉素的释放量随着pH值的增大而增多。结果分析：多数阿霉素分子通过静电吸附作用负载于复合微球内部。pH值显著影响释放速度。微球中负性电荷官能团较多，在低pH值下，负性电荷官能团质子化，不易电离，微球紧缩，导致药物分子难以释放；而在高pH时，官能团电离出质子，微球溶胀，孔道变大，药物释放加快。
Claims (2)
1.一种微米级CS/PAMPS复合微球的制备方法，其特征是首先将壳聚糖、2-丙烯酰胺-2-甲基丙磺酸和N，N-亚甲基双丙烯酰胺按照一定重量比例制备成混合溶液，在氮气保护和引发剂作用下，加热到60℃下反应3小时，使2-丙烯酰胺-2-甲基丙磺酸聚合，得到聚(2-丙烯酰胺-2-甲基丙磺酸)与壳聚糖的混合溶液，再将浓度为25％的戊二醛溶液添加到上述溶液中混合均匀；量取50mL石蜡油置于250mL烧杯中，机械搅拌下滴加1.50g司班80，数分钟后再滴加壳聚糖、聚(2-丙烯酰胺-2-甲基丙磺酸)与戊二醛的混合溶液，乳化半小时后滴加数滴浓盐酸，其用量在0.5mL到2.0mL之间，常温下反应3小时，经乙醇破乳、洗涤后得到直径在100微米到650微米之间的微球，该微球的合成配方按下列条件：
(1)壳聚糖与聚(2-丙烯酰胺-2-甲基丙磺酸)的重量比范围为：3∶2到3∶0.5；
(2)2-丙烯酰胺-2-甲基丙磺酸的聚合用引发剂过硫酸钾，或过硫酸铵，用量占2-丙烯酰胺-2-甲基丙磺酸单体重量的1～5％；
(3)N，N-亚甲基双丙烯酰胺用量占2-丙烯酰胺-2-甲基丙磺酸的0.5％-1％；
(4)壳聚糖与2-丙烯酰胺-2-甲基丙磺酸重量之和占溶液总重量的百分比为2％～5％；
(5)石蜡油与混合溶液体积比范围为3∶1～10∶1。
2.一种丁二酸酐改性微米级CS/PAMPS复合微球的制备方法，其特征是以权利要求1所述方法制备的微球为主体，将该微球与丁二酸酐在二者重量比1∶1到1∶10的范围内混合，加入到50mL N，N-二甲基甲酰胺溶液中，在20～25℃温度范围内反应5小时后过滤微球，用95％乙醇和去离子水依次洗涤，最后真空恒温干燥后得到丁二酸酐改性微米级CS/PAMPS复合微球。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410250398.4A CN105273209B (zh) | 2014-06-09 | 2014-06-09 | 一种改性壳聚糖与聚(2-丙烯酰胺-2-甲基丙磺酸)复合微球的制备 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410250398.4A CN105273209B (zh) | 2014-06-09 | 2014-06-09 | 一种改性壳聚糖与聚(2-丙烯酰胺-2-甲基丙磺酸)复合微球的制备 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105273209A CN105273209A (zh) | 2016-01-27 |
| CN105273209B true CN105273209B (zh) | 2018-05-22 |
Family
ID=55143091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410250398.4A Expired - Fee Related CN105273209B (zh) | 2014-06-09 | 2014-06-09 | 一种改性壳聚糖与聚(2-丙烯酰胺-2-甲基丙磺酸)复合微球的制备 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105273209B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106110334B (zh) * | 2016-08-08 | 2019-11-15 | 江南大学 | 一种表面功能化可载药洗脱微球的制备方法 |
| CN110201215B (zh) * | 2019-06-11 | 2021-07-30 | 科睿驰（深圳）医疗科技发展有限公司 | 一种梯度交联高弹性栓塞微球及其制备工艺 |
| CN112316199B (zh) * | 2020-11-16 | 2022-02-22 | 江南大学 | 一种改性羧甲基壳聚糖微球及其制备方法和应用 |
| CN114478927B (zh) * | 2022-01-26 | 2023-03-28 | 科睿驰（深圳）医疗科技发展有限公司 | 一种栓塞微球及梯度交联制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101240077A (zh) * | 2007-12-19 | 2008-08-13 | 天津大学 | 壳聚糖与丙烯酸-2-丙烯酰胺-2-甲基丙磺酸共聚物共混膜及制备方法与应用 |
| CN101602876A (zh) * | 2009-06-23 | 2009-12-16 | 南京大学 | 高力学强度和电化学活性的多重网络复合水凝胶材料及其制法 |
| CN103113700A (zh) * | 2013-01-18 | 2013-05-22 | 盐城工学院 | 互穿网络结构水凝胶创面敷料及其制备方法 |
-
2014
- 2014-06-09 CN CN201410250398.4A patent/CN105273209B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101240077A (zh) * | 2007-12-19 | 2008-08-13 | 天津大学 | 壳聚糖与丙烯酸-2-丙烯酰胺-2-甲基丙磺酸共聚物共混膜及制备方法与应用 |
| CN101602876A (zh) * | 2009-06-23 | 2009-12-16 | 南京大学 | 高力学强度和电化学活性的多重网络复合水凝胶材料及其制法 |
| CN103113700A (zh) * | 2013-01-18 | 2013-05-22 | 盐城工学院 | 互穿网络结构水凝胶创面敷料及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105273209A (zh) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Malik et al. | Chitosan/xanthan gum based hydrogels as potential carrier for an antiviral drug: Fabrication, characterization, and safety evaluation | |
| He et al. | Advances of molecularly imprinted polymers (MIP) and the application in drug delivery | |
| CN105273209B (zh) | 一种改性壳聚糖与聚(2-丙烯酰胺-2-甲基丙磺酸)复合微球的制备 | |
| Wang et al. | UV-crosslinkable and thermo-responsive chitosan hybrid hydrogel for NIR-triggered localized on-demand drug delivery | |
| CN105250214B (zh) | 一种氨基酸修饰的聚合物纳米水凝胶药物载体的制备方法 | |
| Shrestha et al. | Characterization of a conjugate between Rose Bengal and chitosan for targeted antibiofilm and tissue stabilization effects as a potential treatment of infected dentin | |
| Liu et al. | Effects of ultrasonication on the properties of maize starch/stearic acid/sodium carboxymethyl cellulose composite film | |
| CN101670095B (zh) | 一种用于栓塞治疗的药物组合物及其制备方法 | |
| Barkat et al. | Oxaliplatin‐loaded crosslinked polymeric network of chondroitin sulfate‐co‐poly (methacrylic acid) for colorectal cancer: Its toxicological evaluation | |
| Chen et al. | Effective drug carrier based on polyethylenimine-functionalized bacterial cellulose with controllable release properties | |
| Zhou et al. | Preparation of biodegradable PEGylated pH/reduction dual-stimuli responsive nanohydrogels for controlled release of an anti-cancer drug | |
| CN104306325B (zh) | 一种抗肿瘤水凝胶的制备方法 | |
| Varela-Garcia et al. | Cytosine-functionalized bioinspired hydrogels for ocular delivery of antioxidant transferulic acid | |
| CN109745567A (zh) | 一种dna固定纳米水凝胶微球及其与核酸适配体复合物的制备和应用 | |
| CN104892949A (zh) | 一种谷胱甘肽/pH双重刺激响应离子交联型聚合物纳米水凝胶及其制备方法和应用 | |
| Liang et al. | Light-triggered NO-releasing nanoparticles for treating mice with liver fibrosis | |
| Lu et al. | Preparation and characterization of molecularly imprinted poly (hydroxyethyl methacrylate) microspheres for sustained release of gatifloxacin | |
| Reis et al. | Sustained release of potassium diclofenac from ap H‐responsive hydrogel based on gum arabic conjugates into simulated intestinal fluid | |
| Li et al. | Release of florfenicol in seawater using chitosan-based molecularly imprinted microspheres as drug carriers | |
| CN105131308B (zh) | 一种漆酶/叔丁基过氧化氢催化制备木质素水凝胶的方法 | |
| CN104398504B (zh) | 一种去氧鬼臼毒素类药物的药物组合物及其制备方法和制剂 | |
| Cao et al. | One-step fabrication of multifunctional PLGA-HMME-DTX@ MnO2 nanoparticles for enhanced chemo-sonodynamic antitumor treatment | |
| Elbarbary et al. | Radiation cross-linking of pH-sensitive acrylic acid hydrogel based polyvinylpyrrolidone/2-dimethylamino ethyl methacrylate loaded with betamethasone dipropionate drug and in vitro anti-inflammatory assessment | |
| CN110585116B (zh) | 用于癌症治疗的双响应性甲壳素基纳米凝胶及其制备方法 | |
| Aslam et al. | Green synthesis of quince/pectin cross-linked superporous hydrogel sponges for pH-regulated sustained domperidone delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180223 Address after: 100086 Beijing city Haidian District North Sanhuan Road 43, Tsing Wun contemporary building 12A11 Applicant after: BEIJING ZHITAO SCIENCE & TECHNOLOGY CO., LTD. Address before: School of chemical engineering Jiangnan University No. 1800 214122 Jiangsu city of Wuxi Province Li Lake Avenue Applicant before: Jiangnan University |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Xiaobin Inventor after: Zhu Yongxing Inventor before: Ni Caihua Inventor before: Zhang Meng Inventor before: Zhang Liping Inventor before: Shi Gang |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180426 Address after: 211122 2 dry road, Jiangning District, Nanjing, Jiangsu (Jiangning Gao Xinyuan) Applicant after: Nanjing Shunchang medical science and Technology Co Ltd Address before: 100086 Qingyun contemporary building, 43 North Sanhuan Road, Haidian District, Beijing, 12A11 Applicant before: BEIJING ZHITAO SCIENCE & TECHNOLOGY CO., LTD. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180522 Termination date: 20190609 |